HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts On Avon Buyout Rumor: Easier Turnaround ‘Outside The Public Eye’?

This article was originally published in The Rose Sheet

Executive Summary

Morningstar analyst Eric Lash speculates that the “drastic actions necessary to right Avon’s ship” may be more easily implemented if private equity firm TPG Capital added the direct seller to its portfolio, which already includes Avon Japan. The investment community weighs in on an unconfirmed report that Avon is exploring a potential buyout.

You may also be interested in...



In Brief: Avon Stock Plunges On Rumors; House Microbeads Bill Picks Up Sponsors; More

Avon Counting On 'Beauty For A Purpose' To Inspire Reps, Consumers

Global campaign underscoring Avon's role in female empowerment, including paid media, social networking and a newly created website, should strengthen the company's bond with fans and sales reps while introducing the brand to a new generation of women, CEO Sheri McCoy said during the firm's second-quarter earnings call. Sales dragged again in a challenging macroeconomic climate, but income soared and the firm's North America business was profitable, reflecting effective cost-cutting measures.

In Brief

Expected guidance on lead in cosmetics is still under development, CFSAN says; Avon finalizes settlement with SEC over China bribery charges. More news in brief.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel